Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-d-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer

Nuclear Medicine and Biology

Volumn 38, Issue 4, 2011, Pages 461-475

  Wuest, Melinda ^a   Trayner, Brendan J ^a   Grant, Tina N ^a   Jans, Hans Soenke ^a   Mercer, John R ^a   Murray, David ^a   West, Frederick G ^a   McEwan, Alexander J B ^a   Wuest, Frank ^a   Cheeseman, Chris I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Breast cancer; EMT 6; Fructose metabolism; GLUT5; MCF 7; PET

Indexed keywords

6 DEOXY 6 FLUOROFRUCTOSE F 18; GLUCOSE TRANSPORTER 5; HEPARIN; KETOHEXOKINASE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; FEMALE; FRUCTOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOPHILICITY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RADIOACTIVITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXY SUGARS; FEMALE; FLUORINE RADIOISOTOPES; FRUCTOKINASES; FRUCTOSE; GLUCOSE TRANSPORTER TYPE 5; HUMANS; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS;

EID: 79955478798     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.11.004     Document Type: Article

References (46)

1. Mankoff D.A. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res 2008, 10(Suppl 1):S3.
2. Lee J.H., Rosen E.L., Mankoff D.A. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1-overview, detection, and staging. J Nucl Med 2009, 50:569-581.
3. Lee J.H., Rosen E.L., Mankoff D.A. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2-response to therapy, other indications, and future directions. J Nucl Med 2009, 50:738-748.
4. Munnink T.H.O., Nagengast W.B., Brouwers A.H., Schröder C.P., Hospers G.A., Lub-de Hooge M.N., et al. Molecular imaging of breast cancer. Breast 2009, 18(Suppl 3):S66-S73.
5. Eubank W.B., Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005, 35:84-99.
6. Jadvar H., Alavi A., Gambhir S.S. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009, 50:1820-1827.
7. Buerkle A., Weber W.A. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 2008, 27:545-554.
8. Bastiaannet E., Groen H., Jager P.L., Cobben D.C., van der Graaf W.T., Vaalburg W., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004, 30:83-101.
9. Flier J.S., Mueckler M.M., Usher P., Lodish H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235:1492-1495.
10. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654-662.
11. Manolescu A.R., Witkowska K., Kinnaird A., Cessford T., Cheeseman C. Facilitated Hexose Transporters: new perspectives on form and function. Physiology 2007, 22:234-240.
12. Yamamoto T., Seino Y., Fukumoto H., Koh G., Yano H., Inagaki N., et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990, 170:223-230.
13. Ak I., Stokkel M.P., Pauwels E.K. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000, 126:560-574.
14. Weir L., Worsley D., Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005, 11:204-209.
15. Santiago J.F., Gonen M., Yeung H., Macapinlac H., Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006, 50:61-67.
16. Mavi A., Urhan M., Yu J.Q., Zhuang H., Houseni M., Cermik T.F., et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006, 47:1440-1446.
17. Sundararajan L., Linden H.M., Link J.M., Krohn K.A., Mankoff D.A. 18F-Fluoroestradiol. Semin Nucl Med 2007, 37:470-476.
18. Buck A.K., Schirrmeister H., Mattfeldt T., Reske S.N. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S80-S87.
19. Alavi A., Zhuang H. Finding infection-help from PET. Lancet 2001, 358:1386.
20. Schirmer M., Calamia K.T., Wenger M., Klauser A., Salvarani C., Moncayo R. 18F-fluorodeoxyglucose-positron emission tomography: a new explorative perspective. Exp Gerontol 2003, 38:463-470.
21. Kubota R., Kubota K., Yamada S., Tada M., Ido T., Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994, 35:104-112.
22. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007;11:iii-iv, xi-267.
23. Younes M., Brown R.W., Mody D.R., Fernandez L., Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995, 15:2895-2898.
24. Ravazoula P., Batistatou A., Aletra C., Ladopoulos J., Kourounis G., Tzigounis B. Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol 2003, 24:544-546.
25. Laudanski P., Koda M., Kozłowski L., Swiatecka J., Wojtukiewicz M., Sulkowski S., et al. Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer. Neoplasma 2004, 51:164-168.
26. Kuo S.J., Wu Y.C., Chen C.P., Tseng H.S., Chen D.R. Expression of glucose transporter-1 in Taiwanese patients with breast carcinoma - a preliminary report. Kaohsiung J Med Sci 2006, 22:339-345.
27. Zamora-León S.P., Golde D.W., Concha I.I., Rivas C.I., Delgado-López F., Baselga J., et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci U S A 1996, 93:1847-1852.
28. Godoy A., Ulloa V., Rodríguez F., Reinicke K., Yañez A.J., García Mde L., et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006, 207:614-627.
29. Chan K.K., Chan J.Y., Chung K.K., Fung K.P. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J Cell Biochem 2004, 93:1134-1142.
30. Haradahira T., Tanaka A., Maeda M., Kanazawa Y., Ichiya Y.I., Masuda K. Radiosynthesis, rodent biodistribution, and metabolism of 1-deoxy-1-[18F]fluoro-d-fructose. Nucl Med Biol 1995, 22:719-725.
31. Levi J., Cheng Z., Gheysens O., Patel M., Chan C.T., Wang Y., et al. Fluorescent fructose derivatives for imaging breast cancer cells. Bioconjug Chem 2007, 18:628-634.
32. Yang J., Dowden J., Tatibouet A., Hatanaka Y., Holman G.D. Development of high-affinity ligands and photoaffinity labels for the D-fructose transporter GLUT5. Biochem J 2002, 367:533-539.
33. Trayner B.J., Grant T.N., West F.G., Cheeseman C.I. Synthesis and characterization of 6-deoxy-6-fluoro-d-fructose as a potential compound for imaging breast cancer with PET. Bioorg Med Chem 2009, 17:5488-5495.
34. Richter S., Bergmann R., Pietsch J., Beuthien-Baumann B., Wuest F. Radiosynthesis of N.C.A. sodium [18F]fluoroactetate and radiopharmacological characterization in rats and tumor-xenografted mice. Curr Radiopharm 2008, 1:103-108.
35. Haberkorn U., Ziegler S.I., Oberdorfer F., Trojan H., Haag D., Peschke P., et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994, 21:827-834.
36. Aliaga A., Rousseau J.A., Ouellette R., Cadorette J., van Lier J.E., Lecomte R., et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004, 31:761-770.
37. Laudański P., Swiatecka J., Kovalchuk O., Wołczyński S. Expression of GLUT1 gene in breast cancer cell lines MCF-7 and MDA-MB-231. Ginekol Pol 2003, 74:782-785.
38. Colville C.A., Seatter M.J., Jess T.J., Gould G.W., Thomas H.M. Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J 1993, 290:701-706.
39. Burant C.F., Takeda J., Brot-Laroche E., Bell G.I., Davidson N.O. Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 1992, 267:14523-14526.
40. Smith T.A. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000, 57:170-178.
41. Diggle C.P., Shires M., Leitch D., Brooke D., Carr I.M., Markham A.F., et al. Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Histochem Cytochem 2009, 57:763-774.
42. Douard V., Ferraris R.P. Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab 2008, 295:E227-E237.
43. Amano S., Inoue T., Tomiyoshi K., Ando T., Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998, 39:1424-1427.
44. Jager P.L., de Korte M.A., Lub-de Hooge M.N., van Waarde A., Koopmans K.P., Perik P.J., et al. Molecular imaging: what can be used today. Cancer Imaging 2005, 5:S27-S32. Spec No A.
45. Oswald J., Treite F., Haase C., Kampfrath T., Mäding P., Schwenzer B., et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett 2007, 254:102-110.
46. Robey I.F., Stephen R.M., Brown K.S., Baggett B.K., Gatenby R.A., Gillies R.J. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008, 10:745-756.